Complexity made simple in diffuse large B-cell lymphoma.
Complexity made simple in diffuse large B-cell lymphoma.
复制标题
DOI：
10.1158/1078-0432.ccr-09-1444
复制
发表时间：
2009-09-01
期刊：
影响因子：
--
通讯作者：
Kutok J
中科院分区：
文献类型：
--
作者：
Aster J;Kutok J
弥漫性大B细胞淋巴瘤（DLBCL）是一种异质性疾病，对治疗的反应难以预测。使用一系列五种免疫组织化学标志物（GCET1，CD10，BCL 6，MUM1，FOXP 1）对DLBCL病例进行分类的算法准确预测了接受当前化疗方案治疗的患者的生存率。
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease and response to therapy is difficult to predict. An algorithm to sort DLBCL cases using a series of five immunohistochemical markers (GCET1, CD10, BCL6, MUM1, FOXP1) accurately predicts survival in patients treated with current chemotherapeutic regimens.